Allogène Therapeutics, Inc. (Allo): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage rapide de l'immunothérapie contre le cancer, la thérapie allogène est à l'avant-garde d'une approche révolutionnaire, transformant la façon dont nous conceptualisons les traitements cellulaires. En développant de la pointe hors de l'étagère Les thérapies allogéniques des lymphocytes T des voitures T, l'entreprise est prête à perturber les paradigmes traditionnels de traitement du cancer, offrant des solutions potentiellement plus accessibles et rentables pour les patients luttant contre des tumeurs hématologiques et solides complexes. Leur modèle commercial innovant représente une fusion convaincante de la recherche scientifique avancée, des partenariats stratégiques et des technologies de santé transformatrices qui pourraient redéfinir l'avenir de l'immunothérapie contre le cancer.

Allogène Therapeutics, Inc. (Allo) - Modèle commercial: partenariats clés

Collaboration stratégique avec Pfizer

En octobre 2021, Allogène Therapeutics a conclu une collaboration stratégique avec Pfizer axée sur le développement de la thérapie allogénique des cellules de la voiture T. Les détails clés du partenariat comprennent:

Paramètre de partenariat	Détails financiers
Paiement initial	150 millions de dollars de Pfizer
Paiements de jalons potentiels	Jusqu'à 1,2 milliard de dollars
Focus de développement	Programmes de thérapie allogénique sur les cellules de la voiture T de la voiture T

Partenariats de recherche

Allogène entretient des relations de recherche collaborative avec plusieurs institutions éminentes:

• Université de Californie, San Francisco (UCSF)
• MD Anderson Cancer Center
• Memorial Sloan Kettering Cancer Center

Accords de fabrication

Allogene a établi des partenariats de fabrication avec des organisations de contrats de biotechnologie spécialisées:

Organisation contractuelle	Focus de la fabrication
Groupe Lonza	Capacités de fabrication de thérapie cellulaire
Thérapies avancées Wuxi	Édition de gènes et production de thérapie cellulaire

Accords de licence

Les partenariats sur les licences technologiques comprennent:

• Talen Gene Édition de licence de technologie de l'Université de Californie
• Accords de technologie de plate-forme de cellules de voiture avec des institutions de recherche

Allogène Therapeutics, Inc. (Allo) - Modèle d'entreprise: Activités clés

Développer et faire progresser les thérapies allogéniques de la voiture T

Depuis le quatrième trimestre 2023, la thérapeutique allogène se concentre sur le développement de thérapies allogéniques de la voiture T-Self. La société a 5 candidats de thérapie de voiture primaire dans son pipeline.

Candidate à la thérapie	Type de cancer	Étape clinique
Allo-501	Lymphome non hodgkinien	Phase 1/2
Allo-715	Myélome multiple	Phase 1/2

Effectuer des essais cliniques pour les immunothérapies contre le cancer

En 2023, Allogène a investi 214,7 millions de dollars en dépenses de R&D dédié aux activités d'essai cliniques.

• Essais cliniques actifs sur plusieurs indications de cancer
• Études en cours de phase 1/2 pour les candidats en thérapie principale
• Collaboration avec des établissements universitaires et de recherche

Recherche et optimiser les techniques d'ingénierie cellulaire

La société maintient 3 plateformes technologiques primaires pour l'ingénierie cellulaire:

Plate-forme	Se concentrer	Approche technologique clé
Allocar t	Voiture standard	Ingénierie universelle des cellules T donneurs
ALPHA	Modification des récepteurs des cellules T	Techniques d'édition de gènes

Gestion de la soumission et de la conformité réglementaires

Depuis 2023, l'allogène a 6 Applications actifs de nouveau médicament (IND) avec la FDA.

Développement et protection de la propriété intellectuelle

L'entreprise détient 78 brevets délivrés et 92 demandes de brevet en instance En décembre 2023, en mettant l'accent sur les technologies de thérapie des cellules de voiture T.

Catégorie de brevet	Nombre de brevets	Couverture géographique
Brevets délivrés	78	États-Unis, Europe, Japon
Applications en attente	92	Paysage des brevets mondiaux

Allogène Therapeutics, Inc. (Allo) - Modèle commercial: Ressources clés

Plate-forme d'ingénierie des cellules TPRIETARY ALLOCAR T

La plate-forme propriétaire d'Allogène implique des technologies d'édition géniques avancées, en utilisant spécifiquement les approches de l'édition des gènes Talen et CRISPR. Les capacités de plate-forme clés comprennent:

• Ingénierie universelle des cellules T donneurs
• Techniques de modification des gènes précis
• Développement de la thérapie cellulaire standard

Équipes de recherche et développement de thérapie cellulaire avancée

Depuis le quatrième trimestre 2023, Allogène maintient un personnel de recherche spécialisé avec une composition spécifique:

Catégorie de personnel	Nombre d'employés
Personnel total de R&D	188
Chercheurs au niveau du doctorat	76
Spécialistes de l'immunothérapie	54

Capital financier important

Ressources financières au 31 décembre 2023:

• Equivalents en espèces et en espèces: 484,2 millions de dollars
• Financement total collecté: 687,5 millions de dollars
• Produits des offres publiques: 315,6 millions de dollars

Infrastructure spécialisée de laboratoire et de recherche

Les détails de l'installation de recherche comprennent:

Composant d'infrastructure	Spécification
Espace total des installations de recherche	45 000 pieds carrés
Zones de fabrication certifiées GMP	12 000 pieds carrés
Laboratoires de traitement des cellules avancées	7 laboratoires spécialisés

Portefeuille de propriété intellectuelle

Actifs de la propriété intellectuelle à partir de 2024:

• Demandes totales de brevets: 84
• Brevets accordés: 37
• Demandes de brevet en instance: 47
• Familles de brevets: 12

Allogène Therapeutics, Inc. (Allo) - Modèle d'entreprise: propositions de valeur

Thérapies allogéniques sur les lymphocytes allogéniques sur l'étagère

La thérapie allogène se concentre sur le développement Thérapies allogéniques sur les lymphocytes allogéniques sur l'étagère avec les caractéristiques clés suivantes:

Type de thérapie	Étape de développement	Indication cible
Allo-501	Essai clinique de phase 1	Grand lymphome à cellules B
Allo-501a	Développement préclinique	Lymphome à lycées B en rechute / réfractaire
Allo-715	Essai clinique de phase 1	Myélome multiple

Potentiel de traitements contre le cancer plus accessibles et rentables

La proposition de valeur d'Allogène comprend des avantages potentiels de coûts et d'accessibilité:

• Réduction des coûts de fabrication estimée d'environ 50 à 70% par rapport aux thérapies autologues
• Potentiel d'initiation de traitement plus rapide
• Réduction de la complexité de fabrication spécifique au patient

Approche innovante pour aborder les limites des thérapies cellulaires autologues

Les principales approches technologiques innovantes comprennent:

• TALEN Technologie d'édition de gènes
• Plate-forme universelle de cellules T donneurs
• Ingénierie de cellules Tollocar TPRIÉTAIRE

Ciblant plusieurs indications de cancer avec des immunothérapies transformatrices

Indication du cancer	État du pipeline actuel	Taille du marché potentiel
Grand lymphome à cellules B	Essai clinique de phase 1	3,2 milliards de dollars sur le marché mondial
Myélome multiple	Essai clinique de phase 1	17,5 milliards de dollars sur le marché mondial
Leucémie myéloïde aiguë	Recherche préclinique	1,8 milliard de dollars sur le marché mondial

Amélioration de l'évolutivité et de l'efficacité de la fabrication

Métriques de l'efficacité de la fabrication:

• Le temps de production potentiel réduit à 2 à 3 semaines
• Réduction estimée à 80% du temps de personnalisation spécifique au patient
• Processus de fabrication standardisé

Allogène Therapeutics, Inc. (Allo) - Modèle d'entreprise: relations clients

Engagement avec les professionnels de la santé en oncologie

Allogène Therapeutics maintient un engagement direct avec les professionnels de la santé en oncologie à travers:

Méthode d'engagement	Fréquence	Public cible
Présentations de la conférence médicale	4-6 conférences par an	Oncologues, hématologues
Réunions d'investigation des essais cliniques	2-3 réunions par programme de recherche	Enquêteurs principaux
Communication scientifique personnalisée	Mises à jour trimestrielles	Institutions de recherche

Programmes de soutien aux patients et d'éducation

Les stratégies de relation des patients comprennent:

• Hotline d'informations sur les patients dévoués
• Ressources d'éducation des patients en ligne
• Services de soutien aux participants à l'essai clinique

Communication scientifique régulière et transparence des données cliniques

Canal de communication	Métriques de transparence	Fréquence de rapport
Rapport scientifique annuel	Divulgation de données de l'essai clinique à 100%	Annuellement
Dépôts de la SEC	Mises à jour complètes de progrès de la recherche	Trimestriel
Présentations des investisseurs	Informations détaillées sur les pipelines de recherche	Semi-annuellement

Partenariats de recherche collaborative

Réseaux de collaboration de recherche actuels:

• Memorial Sloan Kettering Cancer Center
• Université de Californie, San Francisco
• MD Anderson Cancer Center

Plateformes numériques pour les informations et les mises à jour de la thérapie

Plate-forme numérique	Engagement des utilisateurs	Type d'information
Site Web de l'entreprise	Visiteurs mensuels du site Web: 25 000	Mises à jour de la recherche, essais cliniques
Page d'entreprise LinkedIn	Abonnés: 15 000	Publications scientifiques, nouvelles de l'entreprise
Webinaires scientifiques	Association trimestrielle du webinaire: 500-750	Discussions d'approche thérapeutique

Allogène Therapeutics, Inc. (Allo) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les spécialistes de l'oncologie

Depuis le quatrième trimestre 2023, Allogène Therapeutics maintient une force de vente spécialisée de 42 représentants axés sur l'oncologie ciblant les principaux leaders d'opinion et les spécialistes de l'hématologie / oncologie.

Type de canal	Nombre de représentants	Target Specialty
Équipe de vente directe en oncologie	42	Spécialistes de l'hématologie / oncologie

Conférences médicales et symposiums scientifiques

En 2023, Allogène a participé à 17 conférences majeures en oncologie, présentant 23 résumés scientifiques et s'engageant avec 1 287 professionnels de la santé.

Métrique de la conférence	2023 données
Les conférences totales ont assisté	17
Résumés scientifiques présentés	23
Les professionnels de la santé engagés	1,287

Plateformes de communication numérique

Allogène utilise plusieurs canaux numériques pour la communication scientifique:

• Site Web de l'entreprise avec 78 342 visiteurs mensuels uniques
• Page d'entreprise LinkedIn avec 24 567 abonnés
• Compte Twitter avec 16 893 abonnés
• Plate-forme numérique des relations avec les investisseurs dédiés

Collaborations avec les centres de traitement du cancer

En 2024, Allogène maintient des collaborations de recherche actives avec 12 principaux centres de traitement du cancer à travers les États-Unis.

Type de collaboration	Nombre de centres	Portée géographique
Partenariats de recherche	12	États-Unis

Canaux de publication réglementaire et scientifique

En 2023, Allogène a publié 19 articles scientifiques évalués par des pairs et soumis 7 communications réglementaires à la FDA et à l'EMA.

Type de publication / communication	Volume 2023
Articles scientifiques évalués par des pairs	19
Soumissions réglementaires	7

Allogène Therapeutics, Inc. (Allo) - Modèle d'entreprise: segments de clientèle

Fournisseurs de soins de santé en oncologie

Depuis le quatrième trimestre 2023, Allogène Therapeutics cible environ 1 500 centres d'oncologie aux États-Unis.

Type de fournisseur	Nombre de clients potentiels
Centres médicaux académiques	250
Pratiques d'oncologie communautaire	1,100
Centres de cancer complets	150

Institutions de recherche sur le cancer

Allogène collabore avec 78 institutions de recherche actives dans le monde.

• Centres désignés de l'Institut national du cancer (NCI): 51
• Partenariats de recherche internationaux: 27
• Collaborations de recherche financées par les NIH: 22

Patients atteints de tumeurs hématologiques en rechute / réfractaires et solides

Cible la population de patients en 2024:

Type de cancer	Patients estimés
Lymphome non hodgkinien	74,200
Myélome multiple	34,470
Tumeurs solides	126,500

Partenaires pharmaceutiques et biotechnologiques

Partenariats pharmaceutiques actifs actuels: 6

• Pfizer Inc.
• Sertier pharmaceutique
• Cellectis S.A.
• Regeneron Pharmaceuticals
• Takeda Pharmaceutique
• GSK (GlaxoSmithKline)

Communautés d'investissement et de recherche

Mesures d'investissement en janvier 2024:

Métrique	Valeur
Capitalisation boursière	629,4 millions de dollars
Investisseurs institutionnels	82.4%
Analystes de recherche couvrant le stock	12

Allogène Therapeutics, Inc. (Allo) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement approfondies

Pour l'exercice 2022, Allogène Therapeutics a déclaré des dépenses de R&D de 311,5 millions de dollars. Les recherches en cours de l'entreprise se concentrent sur les thérapies allogéniques des cellules de voiture T.

Année	Dépenses de R&D	Pourcentage des dépenses d'exploitation totales
2022	311,5 millions de dollars	85.3%
2021	279,4 millions de dollars	83.7%

Gestion et exécution des essais cliniques

L'allogène a plusieurs essais cliniques en cours à travers diverses indications d'oncologie.

• Coûts d'essai cliniques annuels estimés: 150 à 200 millions de dollars
• Essais cliniques actifs: 5-7 programmes simultanés
• Coût moyen par essai clinique Phase: 20 à 40 millions de dollars

Infrastructure de fabrication et de production

La société maintient des installations spécialisées de fabrication de thérapie cellulaire avec des investissements en capital importants.

Usine de fabrication	Emplacement	Investissement en capital estimé
Centre de fabrication primaire	San Francisco, CA	75 à 100 millions de dollars

Processus de conformité et d'approbation réglementaires

Les dépenses de conformité réglementaire sont substantielles dans le secteur de la biotechnologie.

• Coûts de conformité réglementaire annuelle: 15 à 25 millions de dollars
• Coûts de préparation de soumission de la FDA: 5 à 10 millions de dollars par application

Acquisition et rétention de talents

Allogène investit considérablement dans l'attrait des meilleurs talents scientifiques et de gestion.

Catégorie de personnel	Compensation annuelle approximative	Nombre d'employés
Chercheur	$180,000-$250,000	150-200
Leadership exécutif	$500,000-$2,000,000	5-10

Allogène Therapeutics, Inc. (ALLO) - Modèle d'entreprise: sources de revenus

Ventes potentielles de produits futurs des thérapies sur les cellules automobiles

Depuis le quatrième trimestre 2023, les revenus potentiels d'Allogène provenant des thérapies sur les cellules de la voiture sont subordonnés aux futures approbations de la FDA. Aucune vente de produits commerciaux actuelle n'a déclaré.

Accords de collaboration de recherche et développement

Partenaire	Valeur de collaboration	Année
Miserrer	Paiement initial de 150 millions de dollars	2022
Cielo Therapeutics	Conditions financières non divulguées	2023

Payments d'étape provenant de partenariats stratégiques

• Payments de jalons potentiels jusqu'à 1,2 milliard de dollars de la collaboration Merck
• Paiements de jalons contingents sur le développement clinique et les réalisations réglementaires

Revenus de licence potentiels

Aucun revenu spécifique sur l'octroi de licences signalé dans les états financiers de 2023.

Financement de subvention et soutien à la recherche

Source de financement	Montant	Année
California Institute for Regenerative Medicine	3,5 millions de dollars	2022

Revenu total pour 2023: 161,5 millions de dollars, principalement des accords de collaboration et du financement de la recherche.

Allogene Therapeutics, Inc. (ALLO) - Canvas Business Model: Value Propositions

Off-the-shelf (allogeneic) CAR T therapy, eliminating patient-specific manufacturing

The core value proposition is the shift from patient-specific autologous manufacturing to a readily available, allogeneic product. This eliminates the typical wait time associated with autologous CAR T therapies, which is 2-6 weeks for manufacturing. Allogene Therapeutics' cema-cel demonstrated a median time to treatment of Two Days from enrollment in its Phase 1 trials. The global CAR-T market size was estimated at $5.5 billion in 2024, with projections reaching up to $29 billion by 2029. The allogeneic T cell therapies segment itself was projected to grow from $1.16 billion in 2024 to $1.26 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%.

Potential for earlier-line treatment in LBCL (Cema-cel as 1L consolidation)

Cema-cel is being evaluated in the pivotal Phase 2 ALPHA3 trial as a first-line (1L) consolidation strategy for patients with large B-cell lymphoma (LBCL) who test minimal residual disease (MRD) positive after initial chemoimmunotherapy. The trial is designed to compare cema-cel against observation, with a scheduled futility analysis set for 1H 2026. In prior relapsed/refractory (R/R) LBCL trials (ALPHA/ALPHA2) using the pivotal study regimen, the overall response rate (ORR) was 67% and the complete response rate (CR) was 58%. In a subset of patients with low disease burden in those trials, the CR rate reached 100% in some cases. The annual LBCL patient pool in the US, EU, and UK is expected to exceed 60,000 patients. Success in this earlier-line setting could address a market opportunity estimated at $10+ billion.

Simplified logistics and faster delivery to patients compared to autologous CAR T

The operational advantage is quantified by the median time to treatment of Two Days for cema-cel, compared to the 2-6 week wait for autologous products. The ALPHA3 trial has activated over 50 sites across the US and Canada to support broader access. The company's financial stability supports ongoing operations and development.

Financial/Operational Metric	Amount/Period
Cash, Cash Equivalents, and Investments (End Q3 2025)	$277.1 Million
Projected Cash Runway	Into 2H 2027
Q2 2025 Net Loss	$50.9 million ($0.23 per share)
Q2 2025 R&D Expenses	$40.2 million
Q2 2025 G&A Expenses	$14.3 million

First allogeneic CAR T to show clinically significant response in a solid tumor (ALLO-316 in RCC)

ALLO-316, targeting CD70, is the first allogeneic CAR T product to show promise in solid tumors, specifically advanced or metastatic renal cell carcinoma (RCC). In the Phase 1b expansion cohort of the TRAVERSE study, 20 patients received ALLO-316 following lymphodepletion. For the subset of 16 patients with a CD70 Tumor Proportion Score (TPS) ≥ 50%, the Confirmed Overall Response Rate (ORR) was 31%. The dose administered was a single infusion of 80 million AlloCAR T cells. Of the five confirmed responders, four maintain ongoing responses, including one patient in sustained remission for over 12 months. The RCC market is estimated to be worth $3B+ annually.

Expanding CAR T application into large autoimmune disease markets (ALLO-329)

ALLO-329 is an investigational, allogeneic CRISPR-edited CD19/CD70 dual CAR T-cell therapy candidate. The Phase 1 RESOLUTION basket trial began in Q2 2025 across systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The FDA granted Fast Track Designation for these three indications on April 7, 2025. The trial is exploring two lymphodepletion arms: one with cyclophosphamide alone and one with no lymphodepletion. Proof-of-concept data from this trial is planned for 1H 2026. The total addressable market for autoimmune diseases was estimated at $72.34 billion by 2023, with a projected growth rate of 5.5% CAGR until 2032.

• ALLO-329 trial start: Q2 2025.
• ALLO-329 proof-of-concept data expected: 1H 2026.
• Autoimmune TAM (2023): $72.34 billion.

Allogene Therapeutics, Inc. (ALLO) - Canvas Business Model: Customer Relationships

You're managing a pipeline that relies heavily on external partners to get your cell therapy candidates to patients, so the relationship quality with investigators and sites is everything. Allogene Therapeutics, Inc. has built this out by focusing on coordination across a growing network.

High-touch, collaborative relationships with clinical trial investigators and sites

The ALPHA3 trial, which is looking at Cemacabtagene Ansegedleucel (Cema-Cel) as a first-line consolidation therapy for Large B-Cell Lymphoma (LBCL), shows this in action. As of the second quarter of 2025, there were more than 50 sites activated across the U.S. and Canada, with plans to expand to Australia and South Korea in early 2026. Investigators have shown strong enthusiasm, and several sites have proactively worked with Allogene Therapeutics, Inc. to develop and share best practices. The company noted that industry-wide factors had delayed site readiness for screening activities by three months or more after activation in some cases, but the focus on simplification is expected to boost participation. You've seen over 250 patients consented for Minimal Residual Disease (MRD) screening for ALPHA3 to date, with nearly half of those consents coming in the last three months of Q1 2025, showing momentum building at the activated sites.

Direct engagement with key opinion leaders (KOLs) in oncology and rheumatology

Engagement with KOLs is tied directly to the differentiated data emerging from your pipeline assets. For instance, the Phase 1 TRAVERSE trial for ALLO-316 in Renal Cell Carcinoma (RCC) completed enrollment in its Phase 1b cohort, which evaluated the safety and efficacy at dose level 2 (DL2), which is 80M CAR T cells. The positive data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting supports ongoing discussions regarding the pivotal trial design. In rheumatology, the RESOLUTION Basket Trial for ALLO-329 began enrollment in Q2 2025, targeting autoimmune diseases with a design that includes arms with and without lymphodepletion, a key point of interest for KOLs in that space.

Investor relations and communication focused on clinical milestones and cash runway

Your communication strategy centers on disciplined execution and clear financial visibility. You want investors to see the path to value creation through clinical progress. As of the end of the third quarter of 2025, the cash, cash equivalents, and investments balance stood at $277.1 Million. This financial discipline has resulted in a projected cash runway extending into the second half of 2027. The guidance for the full year 2025 reflects this focus on efficiency.

Here's a quick look at the key financial guidance metrics provided for 2025:

Metric	Projected Amount
Expected Decrease in Cash, Cash Equivalents, and Investments	Approximately $150 million
Expected GAAP Operating Expenses	Approximately $230 million
Estimated Non-Cash Stock-Based Compensation Expense (Included in OpEx)	Approximately $45 million

These estimates exclude any impact from potential business development activities, which is an important caveat for analysts.

Scientific and medical affairs support for trial execution and best practices

Scientific affairs directly supports the operational precision you are emphasizing. The ALPHA3 trial's futility analysis, focused on Minimal Residual Disease (MRD) conversion between study arms, remains on track for the first half of 2026. The decision to proceed with the standard Fludarabine and Cyclophosphamide (FC) lymphodepletion regimen in ALPHA3 was supported by early safety and biomarker data, which the medical affairs team helped translate into clear operational guidance for sites. Similarly, for ALLO-329, the first clinical update, which will include both biomarker and clinical proof-of-concept data, is planned for the first half of 2026, allowing for more comprehensive data collection following the mid-2025 trial launch.

Key milestones driving relationship focus include:

• ALPHA3 Futility Analysis scheduled for 1H 2026.
• ALLO-329 Proof-of-Concept Data planned for 1H 2026.
• ALLO-316 Pivotal Trial Design aligned with the FDA.
• Cash runway extending to 2H 2027.

Finance: draft 13-week cash view by Friday.

Allogene Therapeutics, Inc. (ALLO) - Canvas Business Model: Channels

You're looking at how Allogene Therapeutics, Inc. gets its investigational products and corporate message out to the world, which is critical for a clinical-stage company. This is all about access, both for patients in trials and for investors tracking progress.

Global network of academic and community cancer centers for clinical trials

The clinical trial network is the primary channel for patient access to the investigational AlloCAR T™ products right now. This network is built on established relationships with key medical institutions.

As of the second quarter of 2025, Allogene Therapeutics had over 50 clinical sites activated across the United States and Canada, supporting trials like the pivotal Phase 2 ALPHA3 study in Large B-cell Lymphoma (LBCL).

The Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases also had nearly 50 sites across the U.S. activated as of May 2025.

The company is actively planning further expansion, with additional sites in Australia and South Korea progressing toward activation, expected to open in early 2026.

The financial backing for these channels is supported by the company's reported cash position; Allogene Therapeutics ended Q3 2025 with $277.1 Million in cash, cash equivalents, and investments.

Direct communication and presentations at major medical conferences (e.g., ASCO, ASH)

Presenting clinical data at major scientific congresses is a core channel for validating the science and engaging the treating physician community. The company uses these venues to share data from its pipeline candidates like cema-cel (ALPHA3) and ALLO-316 (TRAVERSE).

Allogene Therapeutics presented updated Phase 1 data from the TRAVERSE trial of ALLO-316 at the 2025 ASCO Annual Meeting.

The company also actively engages the investment community through direct presentations, as seen in late 2025:

Event Name	Date (2025)	Time (ET)
TD Cowen Immunology & Inflammation Virtual Summit	November 12	4:30 PM
Jefferies Global Healthcare Conference in London	November 18	5:00 AM
Piper Sandler 37th Annual Healthcare Conference	December 2	12:00 PM

The company also held its Third Quarter 2025 Conference Call and Webcast on November 6, 2025, at 2:00 PM PT / 5:00 PM ET.

Future commercial distribution network via specialty hospitals and treatment centers

While commercial launch is future-facing, the strategy is being shaped by current trial design. The pivotal Phase 2 ALPHA3 study is designed to position cema-cel as a standard "7th cycle" of frontline treatment for eligible LBCL patients with MRD, which implies a broad, yet specialized, distribution model.

The goal is to simplify delivery across community and academic centers, which suggests a network strategy focused on established infusion and cell therapy treatment centers, rather than a broad primary care reach.

• The strategy aims for delivery that is more reliable and at greater scale.
• ALLO-329 is being developed to facilitate broader CAR T adoption in autoimmune indications.
• The company is aligning with the FDA on a pivotal path for ALLO-316 in solid tumors, laying groundwork for potential partnership discussions to advance the program.

Digital and corporate communications for investor and patient awareness

Digital channels are essential for broad, transparent communication with investors and for providing patients information on trial access.

Allogene Therapeutics maintains its corporate presence and information hub at www.allogene.com.

Investor communications are channeled through specific digital assets:

• Investor Relations website for stockholders and analysts.
• Live audio webcasts for major conference presentations and earnings calls.
• Webcast replays are provided on the company website for approximately 30 days following the live event.
• Corporate updates are shared via social media channels, specifically X and LinkedIn.

For patients interested in clinical trials, the company encourages learning more by visiting clinicaltrials.gov, as Allogene does not currently have active Expanded Access protocols.

Allogene Therapeutics, Inc. (ALLO) - Canvas Business Model: Customer Segments

You're looking at the core patient populations Allogene Therapeutics, Inc. is focused on reaching with its off-the-shelf AlloCAR T™ candidates as of late 2025. These segments represent the current clinical trial focus and the potential market for their pipeline products.

The customer segments are defined by the specific investigational product and the disease indication they are targeting:

• Patients with minimal residual disease (MRD)-positive Large B-Cell Lymphoma (LBCL)
• Patients with advanced or metastatic Renal Cell Carcinoma (RCC)
• Rheumatologists and patients with severe autoimmune diseases (e.g., SLE, IIM, SSc)

The treating physicians-oncologists and hematologists-are the direct prescribers and decision-makers for the oncology segments, while rheumatologists are the target for the autoimmune program.

Here's a breakdown of the patient populations and the associated market context:

Oncologists and hematologists treating B-cell lymphomas and renal cell carcinoma

For Large B-Cell Lymphoma (LBCL), Allogene Therapeutics, Inc. is positioning its leading candidate, cema-cel, as a potential standard of care intervention immediately following initial therapy. The ALPHA3 trial is pivotal Phase 2, designed for first-line (1L) consolidation in patients showing minimal residual disease (MRD) after standard treatment like R-CHOP. This positions the product to be the standard "7th cycle" of frontline treatment for eligible LBCL patients with MRD. For advanced or metastatic Renal Cell Carcinoma (RCC), ALLO-316 is being evaluated in the Phase 1 TRAVERSE trial, targeting CD70 expression on these tumors. The company is engaging a network of treating centers; as of Q2 2025, over 50 clinical sites across the United States and Canada were activated for their trials, spanning community cancer centers and major academic institutions.

Patients with minimal residual disease (MRD)-positive Large B-Cell Lymphoma (LBCL)

This segment is defined by the presence of MRD following initial chemotherapy for LBCL. The potential market size for CAR-T therapies targeting B-cells in the U.S. alone is estimated by Allogene Therapeutics, Inc. to be over 2 million patients. The incidence across all currently approved CAR-T indications in blood cancer is estimated around 300,000. The goal is to intervene early, right when MRD is detected, using cema-cel.

Patients with advanced or metastatic Renal Cell Carcinoma (RCC)

ALLO-316 targets CD70 expression in this solid tumor segment. The Phase 1b cohort of the TRAVERSE trial treated 22 patients with lymphodepletion, and 20 received ALLO-316. Of those treated with ALLO-316, 16 patients had a high CD70 Tumor Proportion Score (TPS >50%). In 2024, the U.S. saw over 81,000 new cases of kidney cancer, with RCC being the majority. For Stage IV, advanced RCC, long-term remissions are now possible for a subset of patients, though the five-year survival for Stage III is around 70%.

Rheumatologists and patients with severe autoimmune diseases (e.g., SLE, IIM, SSc)

ALLO-329 is the product candidate for this segment, targeting CD19+ B cells and CD70+ activated T cells, key drivers in autoimmune pathology. The Phase 1 RESOLUTION basket trial launched in Q2 2025 and evaluates conditions including systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis. The total addressable market for autoimmune diseases was estimated at $72.34 billion by 2023, with a projected growth rate of 5.5% CAGR until 2032. The first clinical update for this program is anticipated in 1H 2026.

You need to keep an eye on how these different physician groups perceive the value of an off-the-shelf product versus the established autologous standard. Here's a quick look at the key product/patient alignments:

Product Candidate	Target Indication	Patient Population Focus	Key Trial/Status (Late 2025)
Cema-cel	Large B-Cell Lymphoma (LBCL)	MRD-positive after standard therapy	Pivotal Phase 2 ALPHA3 Trial
ALLO-316	Renal Cell Carcinoma (RCC)	Heavily pretreated advanced/metastatic	Phase 1 TRAVERSE Trial (Enrollment complete in Phase 1b cohort)
ALLO-329	Autoimmune Disease (AID)	SLE, IIM, SSc	Phase 1 RESOLUTION Trial (Launched Q2 2025)

The financial health supports this pipeline focus; Allogene Therapeutics, Inc. ended Q3 2025 with $277.1 Million in cash, cash equivalents, and investments, projecting a cash runway into the 2H 2027. The guidance for 2025 was an expected decrease in cash of approximately $150 million.

Finance: draft 13-week cash view by Friday.

Allogene Therapeutics, Inc. (ALLO) - Canvas Business Model: Cost Structure

You're looking at the cost structure for Allogene Therapeutics, Inc. (ALLO) as of late 2025, which is heavily weighted toward advancing its clinical pipeline. The company's spending reflects its stage as a clinical-stage biotech pioneering allogeneic CAR T (AlloCAR T™) products.

The Cost Structure is dominated by the necessary investment in research and development to move its key assets through late-stage trials. For the third quarter of 2025, Research and Development (R&D) expenses were reported at $31.2 million. This figure includes $2.8 million of non-cash stock-based compensation expense for that quarter. This R&D spend directly funds the ongoing clinical programs, which are the core of the business model right now.

A significant portion of these R&D costs is tied up in high clinical trial costs for pivotal Phase 2 and Phase 1 studies. You see this in the advancement of Cemacabtagene Ansegedleucel (Cema-Cel) in the pivotal Phase 2 ALPHA3 Trial for Large B-Cell Lymphoma (LBCL), which has over 50 sites active across the US and Canada, with international expansion planned for early 2026. Also consuming resources are the Phase 1 RESOLUTION Trial for ALLO-329 in Autoimmune Disease and the Phase 1 TRAVERSE Trial for ALLO-316 in Renal Cell Carcinoma (RCC). The company's allogeneic platform is designed to allow manufacturing of product well in advance and at scale, which is intended to support trial execution while enabling cost reductions over time.

Beyond the lab and clinical sites, manufacturing and process development costs for AlloCAR T products are a critical, ongoing expense. While the exact dollar amount for this specific category isn't broken out from the aggregate R&D, the nature of cell therapy means significant investment is required to scale up the allogeneic manufacturing process, which is key to the platform's economic viability. The company's ability to manufacture product in advance is a structural advantage in managing these costs relative to autologous therapies.

The operational overhead, categorized as General and Administrative (G&A) expenses, was $13.7 million in Q3 2025. This included $5.9 million in non-cash stock-based compensation for the quarter. This spending supports the corporate infrastructure necessary to run the clinical trials and manage the business.

Looking at the full-year picture for 2025, Allogene Therapeutics, Inc. expects its total GAAP Operating Expenses to be approximately $230 million. This guidance, reiterated as of the third quarter update, includes an estimated non-cash stock-based compensation expense of approximately $45 million for the full year. This spending level is set against a cash position of $277.1 million as of September 30, 2025, supporting a cash runway projected to extend into the second half of 2027, with an expected 2025 cash burn of approximately $150 million.

Here's a quick look at the key cost and financial metrics from the Q3 2025 reporting period and the 2025 guidance:

Financial Metric	Q3 2025 Amount (in millions)	2025 Full Year Guidance (in millions)
Research & Development (R&D) Expenses	$31.2	Part of Total Operating Expenses
General & Administrative (G&A) Expenses	$13.7	Part of Total Operating Expenses
Total GAAP Operating Expenses	Not specified for Q3	Approximately $230
Estimated Non-Cash Stock-Based Comp. (Full Year)	$5.9 (for G&A only in Q3)	Approximately $45
Cash, Cash Equivalents, & Investments (End of Q3)	$277.1	N/A
Expected 2025 Cash Burn	N/A	Approximately $150

The company's cost control is evident in the sequential and year-over-year reductions in R&D and G&A expenses for Q3 2025 compared to prior periods. For instance, R&D fell from $40.2 million in Q2 2025, and G&A fell from $14.3 million in Q2 2025. This disciplined approach to OpEx is what helped the company beat EPS expectations for the quarter.

The primary cost drivers, R&D and G&A, are detailed below:

• Dominant Research and Development (R&D) expenses: $31.2 million in Q3 2025.
• High clinical trial costs for pivotal Phase 2 and Phase 1 studies.
• Manufacturing and process development costs for AlloCAR T products.
• General and Administrative (G&A) expenses: $13.7 million in Q3 2025.
• Total 2025 GAAP Operating Expenses expected to be approximately $230 million.

Allogene Therapeutics, Inc. (ALLO) - Canvas Business Model: Revenue Streams

You're looking at the revenue side for Allogene Therapeutics, Inc. (ALLO) as of late 2025, and honestly, it's what you expect for a company deep in the clinic: the money is coming from the balance sheet, not the patient.

Minimal to zero product sales revenue, as a clinical-stage company

As of the third quarter of 2025, Allogene Therapeutics, Inc. reported $0 in revenue for the quarter ending September 30, 2025. This reflects the reality of a clinical-stage biotech; there are no approved products generating sales yet. Analyst consensus for Q3 2025 revenue also modeled this at $0M. The entire financial model right now is built around managing the cash burn until a potential approval event.

Collaboration and license revenue from strategic partners like Servier

The specific revenue stream from the Servier collaboration, which involved anti-CD19 products, is no longer active, as Servier withdrew from that partnership in 2022. For the three months ended March 31, 2025, the reported collaboration revenue-related party-was listed as $- (a dash) in one filing snippet, further supporting the current lack of material collaboration income. The focus has shifted to internal pipeline execution, meaning this stream is currently negligible or zero.

Interest income generated from cash and investments

Since product sales and collaboration revenue are effectively absent, the primary source of non-operating income is interest earned on the substantial cash reserves. As of September 30, 2025, Allogene Therapeutics, Inc. held $277.1 Million in cash, cash equivalents, and investments. This balance is the foundation supporting operations, which are projected to continue into the second half of 2027. The interest income generated from this pool is critical for offsetting a portion of the operating expenses.

Here's a quick look at the financial position underpinning this income source:

Metric	Amount (as of Q3 2025)
Cash, Cash Equivalents, and Investments	$277.1 Million
Projected 2025 Cash Burn	Approximately $150 Million
Projected Full-Year 2025 GAAP Operating Expenses	Approximately $230 Million
Projected Cash Runway End Date	Second half of 2027

Potential future milestone payments from existing or new collaborations

The near-term value realization is tied directly to clinical progress, which could trigger milestone payments from potential future deals or existing agreements not explicitly detailed as current revenue. You should watch these catalysts closely:

• ALPHA3 Trial (cema-cel in LBCL): MRD-based futility analysis expected in the first half of 2026.
• RESOLUTION Trial (ALLO-329 in Autoimmune Disease): Initial biomarker and proof-of-concept data targeted for the first half of 2026.
• TRAVERSE Trial (ALLO-316 in RCC): Alignment with the FDA on a pivotal trial design is laying groundwork for potential partnership discussions.

Future product sales revenue contingent on regulatory approval of Cema-cel or other candidates

This is the ultimate revenue goal. The potential for product sales revenue is entirely contingent on the successful progression through the remaining clinical stages and subsequent regulatory approval for the lead candidate, cema-cel, in large B-cell lymphoma (LBCL), or for ALLO-316 in renal cell carcinoma (RCC). The company is positioning its platform to bring 'off-the-shelf' cell therapy earlier in disease, which, if successful, would unlock significant commercial revenue streams starting sometime after 2026.